Botanilogics — Plant Perception Profiles

Coming Soon

At Botanilogics, we define plant-based products by their measured chemistry and blinded human perception — published only when effects pass a pre-set statistical gate. Cannabis is the starting point; the standard is built for plant-based medicine as a whole — and the mandate now runs at industrial scale, with a live dataset programme covering more than 800,000 planted trees across 100+ farms in four countries.

Launch updates only.

Enter Site →

Explore the full site behind this page — Home, The Profile, Evidence, Programmes, Partners, and About & Contact.

Visit Luma Leaf ↗

Luma Leaf is one of Botanilogics’ consumer brands — Cannabis, Illuminated. See Perception Profiles in consumer form: profiles, current lots and the science behind them.

© 2026 Botanilogics · Plant Perception Profiles™ · Patent pending

Botanical data & IP platform · From cannabis to commercial agriculture

Plant medicine, defined by evidence — not by name.

Cannabis is our starting point, not our destination. Botanilogics builds Plant Perception Profiles™ — for each lot, full laboratory chemistry paired with blinded human-perception panel results, with an effect published only when it passes a pre-set statistical gate — as a measurement standard for plant-based medicine as a whole. The same discipline now operates at commercial, industrial scale: our mandate has expanded to a live dataset programme on a plantation estate of more than 800,000 planted trees, across more than 100 farms in four countries.

Illustration of a botanical plant overlaid with a molecular network of connected nodes
76
chemovars profiled in the completed research programme
~827
blinded panel responses collected, 2023–2025
54
papers in the whole-plant human-evidence library, 31 of them human studies
17 of 76
chemovars produced an effect that passed the publish gate — reported openly, attrition included

Savor Sciences research programme, 2023–2025, and its whole-plant evidence review

The expanded mandate

A second proving ground — at commercial, industrial scale.

Botanilogics’ plan has expanded beyond the cannabis proof of concept. The platform now carries a defined programme of work on a confidential plantation estate dataset: a real-time commercial plantation programme growing Paulownia, a high-value hardwood, across North and Central America. It is one of the largest field datasets of its kind — more than a decade of planting records in which success and failure are both on the record, farm by farm, vintage by vintage.

842,197
planted trees recorded across the estate dataset
434,080
surviving trees in the current verified inventory
100+ farms
under 467 grower contracts, across four countries
10+ years
of planting, survival and harvest data — failures recorded alongside successes

Plantation estate dataset, as consolidated in Botanilogics’ programme of work, November 2026

SCOPE 01 · VERIFY

A certified inventory

Farm, contract and planting records consolidated into one dataset and checked against the field — including drone-census monitoring — so the inventory the enterprise is valued on is an inventory that has been verified, not asserted.

SCOPE 02 · ANALYSE

Survival, success and failure

With over 800,000 planted units, the dataset supports real survival analysis: which genetics, sites, soils and farming practices produced trees that lived and grew — and which did not, and why. Failure data at this scale is what most plantation datasets discard; it is where the predictive value sits.

SCOPE 03 · FORECAST

Yield and harvest, predicted

Planting and projected harvest mapped by year and by country — the logistics of a multi-year harvest programme, and forecast board-feet of high-value lumber from a growing, certified inventory. The same evidence discipline as the Profile, pointed at enterprise value.

The problem

A plant name is not a specification.

Cannabis makes the problem impossible to ignore — two lots sold under one strain name can differ in chemistry, and the same chemistry can feel different from lot to lot — but it runs across plant-based medicine: products are priced and recommended on names, traditions, reputations and uncontrolled reviews, while their effects are claimed far more often than they are properly measured. Three findings from our cannabis evidence review show why that fails:

FINDING 01

Self-reports inflate effects 3–5×

Across the whole-plant human literature, uncontrolled self-reports run three to five times larger than placebo-controlled effects. Every crowd-review and critic-score product in the market is unblinded.

FINDING 02

Chemistry alone doesn’t predict perception

Our own chemistry-only classifier scored 100% in-sample — and about 32% cross-validated. A certificate of analysis cannot tell you what a product does. That failure is why the human layer exists.

FINDING 03

More THC is not more relief

In the panel data, higher THC was associated with less pain relief, and the dose-ranging trials put the analgesic plateau near 1–2.5 mg of inhaled THC — while side effects keep rising with dose.

The horizon

Cannabis is the starting point. Plant-based medicine is the field. Commercial Agriculture is the target.

Cannabis is where the method is being proven first — it is the largest, most data-poor and most immediately commercial botanical market. The asset being built is bigger than any one plant: a measurement standard for any botanical whose effects are claimed but never properly measured. The same gap the Profile closes in cannabis — claimed effects, unblinded measurement — runs across the whole of plant-based medicine. And the method has already travelled once: the estate dataset programme applies it, live, to commercial agriculture at industrial scale.

NOW · PROOF OF CONCEPT

Cannabis, measured properly

The operating programme today: 76 chemovars profiled, blinded panels running, and the first lot cards issued on real data. This is where the standard earns its credibility — in the open, attrition included.

SCOPED IN THE RESEARCH

A Key Plants library of 30

The research programme already looks beyond cannabis: a Key Plants library of 30 target plants for medicinal purposes is scoped inside the group’s integrated research programme — the map of where the Profile goes next.

NOW · LIVE AT SCALE

Commercial agriculture — at estate scale

The first transfer of the standard beyond medicine is already operating: a defined dataset programme on a Paulownia plantation estate of 842,197 planted trees across 100+ farms in four countries — verified inventory, survival analysis and harvest forecasting on a decade of success and failure data.

IN PLANNING

The wider botanical field

Group planning extends the same infrastructure across plant-based medicine over time — functional mushrooms, adaptogens such as ashwagandha and ginseng, and functional botanicals such as green tea among the categories in view. Planning, not product claims: no non-cannabis panels are represented as operating.

The protocol

Four steps. One gate. Nothing published that doesn’t pass.

The method is plant-agnostic by design — chemical fingerprinting, blinded human perception, a pre-set publish gate. It does not change from plant to plant; that is what makes profiles comparable, and the standard transferable.

1

Laboratory chemistry

A full ISO/IEC 17025 panel — cannabinoids, terpenes and related analytes — run on the specific lot, under chain of custody.

2

Blinded perception panel

A trained panel evaluates coded samples blind — standardised dose, defined device protocol — with no brand, price or identity cues.

3

Statistics & the publish gate

Results are reported with confidence intervals and false-discovery adjustment. An effect is labelled VALIDATED only if it passes the gate.

4

The lot card

Chemistry and panel results side by side on a retail card — negative results printed, not suppressed.

Programmes

What the platform is working on

The programmes below start in cannabis, the proof of concept — and one is already running far beyond it. The data-licensing, platform-services and AI-validation work is built to transfer to other plant categories without redesign; the estate dataset programme is that transfer, operating now at commercial scale.

Plantation estate dataset programme

Our flagship mandate beyond cannabis: verification, survival analysis and harvest forecasting across a Paulownia estate of more than 800,000 planted trees, 100+ farms and four countries — a real-time commercial programme, not a pilot.

Low-dose product design

A research programme designing low-THC / higher-CBD chemovars around the dose plateau — THC dose first, CBD ratio second, terpenes as a testable third layer.

Profile licensing

Cultivators and brands keep their genetics; Botanilogics licenses the chemistry-and-perception layer — profiles, lot cards and branded product programmes.

AI validation partnerships

AI drug-discovery partners make locked, pre-registered predictions about chemistry → perceived effects. We validate them blind through the panel platform.

Our consumer brands

Luma Leaf — Cannabis, Illuminated.

Luma Leaf is one of Botanilogics’ consumer brands — where Perception Profiles meet the shelf: profiled products, current lots and the science presented in consumer form, powered by Botanilogics Perception Profiles™.

The Profile

One lot. Its chemistry, and what a blinded panel actually perceived.

A Plant Perception Profile™ is generated per chemovar and per lot, through a fixed protocol. The method doesn’t change from lot to lot — or from plant to plant. It is built as a general standard for plant-based medicine that happens to start with cannabis, not as a cannabis-only tool — and that is what makes profiles comparable, and licensable.

Illustration of an analytical laboratory bench with sample vials, a potted plant and a chromatogram on a monitor
1

Chemistry

Full ISO/IEC 17025 laboratory panel on the specific lot — cannabinoids, terpenes and related analytes — with Metrc chain of custody through licensed operators.

2

Blinded panel

A trained panel (n=25 in the operating model) evaluates coded samples blind: a standardised 0.4 g dose via a defined vaporiser protocol, recording perceived effects and sensory attributes.

3

The gate

Effects are reported with Wilson confidence intervals and Benjamini–Hochberg false-discovery adjustment. VALIDATED means the effect survived the gate. Everything else prints as NOT VALIDATED.

4

The artefact

The MEP lot card: lot chemistry beside blinded-panel results, with honest-limits disclosures, California warnings and an FDA not-evaluated statement — at the point of sale, and by QR code on profiled products.

The first cards on real data

Operating panels ran in Fall 2026 with an ISO/IEC 17025-accredited laboratory. These are the first two lots profiled end-to-end. Note what the cards refuse to say: on both, every symptom-relief item is NOT VALIDATED — so the cards don’t claim it.

LuLu Lemon
MEP Lot Card · Fall 2026 panel
Real panel & lab data

Lot chemistry — ISO/IEC 17025

Cannabinoid panelper-lot values
Terpene panelper-lot values
LaboratoryAccredited lab
Chain of custodyMetrc

Blinded panel — perceived effects

  • Uplifted Validated
  • Euphoric Validated
  • Pain relief Not validated
  • All symptom-relief items Not validated
Effects are labelled VALIDATED only where they pass the pre-set statistical gate (Wilson confidence intervals; Benjamini–Hochberg adjustment). Panel results describe perception in a blinded setting; they are not medical claims. These statements have not been evaluated by the FDA.
Granddaddy Purple
MEP Lot Card · Fall 2026 panel
Real panel & lab data

Lot chemistry — ISO/IEC 17025

Cannabinoid panelper-lot values
Terpene panelper-lot values
LaboratoryAccredited lab
Chain of custodyMetrc

Blinded panel — perceived effects

  • Comfort Validated
  • Euphoric Validated
  • Sleepy Validated
  • All symptom-relief items Not validated
Effects are labelled VALIDATED only where they pass the pre-set statistical gate (Wilson confidence intervals; Benjamini–Hochberg adjustment). Panel results describe perception in a blinded setting; they are not medical claims. These statements have not been evaluated by the FDA.
Why the gate matters. In the completed research programme, 17 of 76 chemovars produced at least one effect that passed the publish gate — and only 2 survived the strictest false-discovery threshold. We publish that attrition rather than hide it. A profile that can fail is the only kind worth trusting.

Asset sample — the template card

The 11×17 card below is the template every profiled lot follows, shown under the placeholder grower name Luma — a stand-in used until a partner name is cleared for publication. Its data are illustrative — this is not a real lot and nothing on this card is for sale — but the layout, chemistry panel, confidence ranges and publish gate are exactly as issued: this is the format a cultivator, brand or retailer receives as their asset. The same template carries the real lots above; only the data change.

Luma — Sample Chemovar A
Sample lot profile · This jar · Lot profile · Dried flower · THC-dominant
Illustrative data
Template sample
LotPlaceholder lot no.
PanelBlinded · n=25 · Fall 2026
Dose0.4 g · Pax vaporizer
Validated1 validated effect
HarvestedSep 28, 2026
PackagedNov 14, 2026
Net weight3.5 g
Grown inCalifornia

Chemistry — measured in this lot

Total THC22.4%
THCa24.8%
Total CBD<0.1%
CBG0.6%
Total cannabinoids26.1%

Leading terpenes

β-Myrcene0.71%
d-Limonene0.44%
β-Caryophyllene0.38%
α-Pinene0.12%
Total terpenes2.06%

Issued cards carry the lot’s Metrc UID and licence numbers; both are omitted on this placeholder sample.

Medicinal Effects Profile — what the panel reported

  • EnergyValidated

    17 of 25 reviewers (68%; 95% range 48%–83%). Typical across chemovars: 22%–35%.

  • CalmNot validated

    19 of 25 reviewers (76%; range 57%–89%). Not distinguishable from the typical 66%–74%.

  • RelaxationNot validated

    15 of 25 reviewers (60%; range 41%–77%). Not distinguishable from the typical 57%–67%.

  • Pain ReliefNot validated

    9 of 25 reviewers (36%; range 20%–55%). Not distinguishable from the typical 16%–28%.

  • SleepinessNot validated

    4 of 25 reviewers (16%; range 6%–35%). Not distinguishable from the typical 20%–32%.

Share of blinded panel reviewers who reported each effect, with its 95% confidence range. An effect is validated only when its whole range sits above how often reviewers report that effect across all chemovars.

Reading this profile

A validated effect is a likelihood, not a promise — some patients will not experience it. Results come from experienced adult reviewers using a vaporizer at a set dose; other methods, doses and individuals can differ. This profile applies to this chemovar as grown and tested. It is not a treatment for any disease — talk with your physician about whether this product fits your care.

Method — how this chemovar was validated

  1. Chemistry. Each lot is tested by an ISO/IEC 17025-accredited laboratory for 13 cannabinoids and 25 terpenes.
  2. Blinded panel. Reviewers receive unlabeled samples and report effects without knowing the chemovar.
  3. Statistics. Each effect gets a Wilson 95% confidence range, adjusted for multiple comparisons (Benjamini–Hochberg).
  4. Publish gate. Only effects whose lower bound exceeds that effect’s typical rate across all chemovars are labeled validated.

Government warning (as printed on the card): This product contains cannabis, a Schedule I controlled substance. Keep out of reach of children and animals. For use only by adults 21 years of age and older or by qualified patients with a physician’s recommendation. Do not use if pregnant or breastfeeding — cannabis use while pregnant or breastfeeding may be harmful. Consumption of cannabis impairs your ability to drive and operate machinery; please use extreme caution.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Luma (placeholder grower name) · California · Cultivator and distributor licence numbers appear on issued cards · Effects methodology © Savor Sciences, Inc. · Patent pending

Source: MEP 11×17 sample lot profile — SAMPLE LOT PROFILE · ILLUSTRATIVE DATA, with the grower name shown as the placeholder “Luma”. Shown as the template / asset sample; pair with the real-data cards above for issued lots.

Evidence

The evidence standard the platform is built on

Botanilogics’ science is executed by Savor Sciences, Inc. (SSI). Two research programmes anchor the platform: a completed blinded-panel study of 76 cannabis chemovars and a whole-plant cannabis human-evidence review, now in its second edition — a 54-paper library, 31 of them human whole-plant studies. Cannabis is the proving ground; the standard those programmes establish is the one the platform carries to plant-based medicine generally.

What the literature says

Whole-plant human data are rare, and what exists is mostly uncontrolled. The review’s central finding: uncontrolled self-reports inflate perceived effects three to five times versus blinded, placebo-controlled measurement. Strain names, crowd reviews and critic scores all sit on the uncontrolled side of that gap. Blinded panels are how you close it — in cannabis first, and in every botanical category where tradition and testimony currently stand in for measurement.

Chemistry alone doesn’t predict perception

Accuracy of our internal chemistry-only effect classifier (completed research programme). Perfect on the data it was trained on; near chance on data it hadn’t seen.

In-sample 100% Cross-validated ~32% 0% 100% Classifier accuracy — the stated reason the human panel layer exists

Relief plateaus early. Side effects don’t.

Schematic of the dose-ranging synthesis in the evidence review (five trials): analgesia plateaus near 1–2.5 mg inhaled THC while adverse effects keep rising with dose.

plateau ≈1–2.5 mg pain relief side effects 0 inhaled THC dose (mg) 10

Signals that survived the gate

THC

THC → Energy. In the blinded panel data, THC was the strongest validated correlate of energy-related ratings — the clearest signal in the programme. Effect sizes and model statistics are part of the licensed dataset and are not published here.

CBD

CBD → Pain relief. CBD was associated with higher pain-relief ratings. Notably, higher THC was associated with less pain relief — a non-obvious finding with direct consequences for product design.

2 of 76

Survived the strictest correction. Seventeen chemovars produced at least one gated effect; only two survived the strictest false-discovery threshold. Both numbers are published. That is the standard every future profile is held to.

The working order the evidence supports: THC dose first, CBD ratio second, terpenes a testable third layer. That order drives the low-dose programme; the detailed design rules behind it are programme material, shared with partners under agreement — and they are hypotheses under test, not product claims.

The same discipline, at plantation scale

The evidence standard above now also governs the platform’s largest dataset. In the estate programme, Botanilogics works on a plantation record of 842,197 planted trees — of which 434,080 survive in the current inventory. The gap between those two numbers is not hidden or averaged away: it is the dataset. Survival and failure are analysed by farm, vintage, genetics and site across more than 100 farms in four countries, exactly as panel attrition is published rather than suppressed in the cannabis programme. A dataset that keeps its failures is the only kind a forecast can be built on.

Sources: Savor Sciences completed panel research report and whole-plant evidence reviews, 2023–2026; Plantation estate dataset, November 2026. Full research texts are shared with partners under agreement — contact us to start that conversation.

Programmes

Research and licensing programmes built on the Profile

Botanilogics is asset-light: it does not grow, manufacture or sell cannabis. It builds the data layer — and licenses it. Most programmes below are stated for cannabis, the proof of concept; the architecture is deliberately botanical-general, designed so the same data layer repeats across the totality of plant-based medicines. The first programme listed is the proof that it travels: a live, commercial-scale deployment in plantation agriculture.

Flagship · Live programme

The plantation estate dataset project — commercial agriculture at industrial scale

Botanilogics’ mandate now includes a defined scope of work on a confidential plantation estate — a real-time commercial and industrial-scale programme growing Paulownia, a high-value hardwood, across more than 100 farms in four countries in North and Central America. The dataset records 842,197 planted trees and a current surviving inventory of 434,080 trees under 467 grower contracts, with more than a decade of planting history in which failures are recorded with the same care as successes. That completeness is rare in plantation data, and it is what makes the dataset commercially valuable: models trained only on survivors learn nothing about risk.

The scope of work runs in four parts. (1) Consolidation: farm, contract, planting and harvest records from across the estate brought into a single, auditable dataset. (2) Verification: the recorded inventory checked against the field, including drone-census monitoring, toward a certified inventory the enterprise can be valued on. (3) Analysis: survival and performance analysed by genetics, site, soil, vintage and farming partner — what grew, what failed, and what distinguishes them. (4) Forecasting: planting and projected harvest mapped by year and by country, so harvest logistics and forecast lumber yield — board-feet of high-value hardwood from a certified, growing inventory — rest on measured data rather than projection by assertion.

This is the Botanilogics method operating outside medicine for the first time: the same refusal to publish what has not been verified that governs the Perception Profile gate, applied to a plantation estate. It expands the platform’s mandate, its dataset and its addressable work by an order of magnitude — from laboratory lots to a multi-country agricultural enterprise, in real time.

Programme figures: Plantation estate dataset as consolidated in Botanilogics’ programme of work, November 2026. Detailed estate data is programme material, shared with partners under agreement.

Research programme

Low-THC / higher-CBD chemovar design

Built on the low-dose literature: analgesia plateaus around 0.5–2.5 mg of inhaled THC while side effects keep rising. The programme designs chemovars to that plateau instead of to maximum THC, and tests them through the same blinded panel platform. Specific chemovar targets, breeding methods and programme design are developed with partners and shared under agreement — they are not published here.

Licensing

Chemovar data licensing

Perception Profiles licensed to brands and cultivators. Partners keep their genetics and their brands; Botanilogics licenses the chemistry-and-perception layer — the profile, the data and the right to publish gated results.

Licensing

Profiled-product programmes

Lot-level MEP cards and profile-led products sold through licensed channels, with a certified-retailer programme for dispensaries that stock profiled lots and present the cards at the point of sale. A first pilot retail channel is in preparation in California.

Research programme

Breeding & genetics

Data-led chemovar development: breeding decisions made against panel and chemistry data rather than yield and THC alone. Genetic identity and chemical expression are different things — which is why genetics, chemistry and perception are measured and licensed as separate layers.

Partnership

AI validation partnerships

AI drug-discovery partners make locked, pre-registered predictions about cannabis chemistry → perceived effects — no novel compounds, non-clinical. The predictions are validated blind through the panel platform. Engagements are scoped individually and proceed under NDA; commercial and publication terms are agreed per engagement and are not published.

Horizon · In planning

Beyond cannabis — the Key Plants horizon

Cannabis is merely the starting point. The research programme already scopes beyond it: a Key Plants library of 30 target plants for medicinal purposes sits inside the group’s integrated research programme. Group planning extends the same infrastructure — chemistry, blinded perception, the publish gate — across plant-based medicine over time, with functional mushrooms, adaptogens (such as ashwagandha and ginseng) and functional botanicals (such as green tea) among the categories in view. The consumer-brand layer is designed to repeat the same way: a brand per category, Luma Leaf for cannabis first, sister brands for later botanical categories.

Status, stated plainly: the Key Plants library is scoped in the research; the wider categories are planning, not operating programmes, and no effects are claimed for any plant beyond the cannabis evidence on this site.

Services

Panel & qualification services

Blinded panel programmes run for partners, and vendor-qualification services built on the group’s quality-management resources — timely in a market where compliant supply chains and documented vendor files are becoming a condition of operating. Programme pricing is scoped per engagement and is not published.

Partners

Work with the platform

Every engagement runs the same way: your product, our protocol, results published only through the gate. Pilot partners are onboarded under NDA; partner names are published only once agreements are in place. Today’s pilots are in cannabis — the starting point — and the platform’s largest live programme is in commercial agriculture, on a confidential plantation estate. Botanical partners in the wider plant-medicine categories in our planning are welcome in the same conversation.

Cultivators & brands

Profile your chemovars and lots. You keep your genetics; you license the chemistry-and-perception layer — and you can publish the results that pass the gate, which is precisely why they’re worth publishing.

Retailers

Stock profiled lots and present MEP lot cards at the point of sale through the certified-retailer programme — consumer information that is panel data, not marketing copy.

Laboratories

ISO/IEC 17025 chemistry is the first layer of every profile. We work with accredited labs under chain of custody, and lab partners are qualified before programme design locks.

AI & research partners

Lock your model’s predictions, pre-register them, and have them tested blind against human perception. A validation that can fail is the only kind your counterparties will believe.

Plantation & commercial agriculture operators

The estate programme shows the platform at industrial scale: verified inventory, survival analysis and harvest forecasting across estates of hundreds of thousands of planted units. If you operate plantations or agricultural programmes whose records have never been consolidated into a decision-grade dataset, that is the work we now do at scale.

Botanical partners beyond cannabis

The Profile is a general standard, not a cannabis-only tool. If you work with a plant medicine whose effects are claimed but never properly measured — in the functional-mushroom, adaptogen or functional-botanical categories in our planning, or beyond them — the same protocol applies, and the Key Plants horizon is where that work begins.

How an engagement runs

Four steps, same as the protocol

1

Introduction

A short call and an NDA. We scope the chemovars, lots or predictions you want tested.

2

Protocol

The design is fixed and documented before anything is sampled — dose, device, panel, gate.

3

Panel

Accredited-lab chemistry and blinded panel sessions run under chain of custody.

4

Profile

You receive the full profile — validated and not-validated results alike — and the lot card, if the lot goes to retail.

About

An asset-light data company, working at industrial scale

Botanilogics is the commercialisation brand and vehicle for Plant Perception Profiles™ inside the Botanalogics Inc. group. The science is held and executed by Savor Sciences, Inc. (SSI) — the panel platform, the research programme and the patent-pending methodology (U.S. provisional application filed August 27, 2026). Its managing team — Dr. Patrick J. Sullivan, Chad Cruchley and Lenny Karmiol — also leads the group’s wider data-programme and diligence work.

Cannabis is merely the starting point. It is the proof of concept — chosen because it is the largest, most data-poor and most immediately commercial botanical market — but the ambition is the totality of plant-based medicines: the profile is the product, and it is built to travel to other botanicals. The research already scopes that wider field through a Key Plants library of 30 target plants, and group planning extends the same infrastructure over time to categories such as functional mushrooms, adaptogens and functional botanicals. What Botanilogics is building, in one line, is the measurement standard for plant-based medicine — proven in cannabis first.

That wider mandate is no longer only a plan. Botanilogics now carries a defined programme of work on a confidential plantation estate dataset — a real-time commercial plantation programme of 842,197 planted Paulownia trees across more than 100 farms in four countries, with 434,080 surviving trees in the current inventory and more than a decade of success and failure data behind them. Verifying that inventory, analysing what grew and what did not, and forecasting harvest and lumber yield from it is the platform’s first commercial-scale application — and it changes the scale of everything the company does: the datasets are larger, the counterparties are industrial, and the questions the data answers carry enterprise value.

Dr. Patrick J. Sullivan

Partner · CEO, Botanalogics Inc.

Author of the SSI research programme — the evidence reviews, the panel methodology and the AI validation partnership concept.

Chad Cruchley

Partner

Brings the cannabis extraction and analytics network — the operators, labs and channels the platform profiles and sells through.

Lenny Karmiol

Partner

Brings the pharma-logistics network; leads the group’s capital and deal work.

  • 2023 – 2025

    Blinded panel corpus built: 76 chemovars, ~827 responses.

  • Aug 27, 2026

    U.S. provisional patent application filed (methodology) — patent pending.

  • Oct 2026

    Panel research report and whole-plant evidence reviews completed.

  • Fall 2026

    First operating panel sessions run with an ISO/IEC 17025 panel laboratory; first MEP lot cards issued on real panel and lab data.

  • Nov 2, 2026

    Evidence review of record updated: 54-paper library, dose-plateau synthesis.

  • Nov 2026

    Mandate expanded: the plantation estate dataset project — a defined programme of work on a plantation estate of 842,197 planted trees across 100+ farms in four countries, the platform’s first commercial, industrial-scale application.

Contact

For partnership, licensing and panel-programme enquiries, use the form. No public email address is published while the domain’s mail service is being configured — at launch, this form is the contact route.

Botanilogics does not publish investor materials on this site, and nothing here is an offer of securities. Partner names are published only with agreements in place.

Thank you — your enquiry has been sent. We'll be in touch shortly.

We reply to partnership enquiries from this form only. Please don’t send confidential material until an NDA is in place.